The new SumiShield 50WG insecticide, which possibly has longer duration of effectiveness than other indoor residual spray (IRS) formulations, has potential as an alternative IRS product for malaria vector control, particularly where resistance to other formulations has developed.
A workshop on ticks and tick-borne diseases (T&TBDs) was held on June 25 and 26, 2019, at the Tropical Pesticides Research Institute, Division of Livestock and Human Diseases Vector Control, Arusha, Tanzania. The objectives of the workshop were to discuss the current situation and to formulate actionable strategies to improve surveillance and control of T&TBDs in Africa. The workshop was funded by the National Research Foundation and the Cape Peninsula University of Technology and attended by livestock health providers, farmers, and researchers from East, West, and Southern African countries. During the workshop, experts presented recent surveillance data focused on T&TBDs; participants discussed research opportunities and community engagement. The primary outcome of the workshop was the creation of a new research consortium known as The African Consortium for T&TBDs. The consortium is intended to function as a community for researchers, students, farmers, policymakers, extension workers, and community members who are interested in the advancement of T&TBD control. The consortium will engage in research activities that focus on comprehensive surveillance of T&TBDs, developing tick acaricide resistance, alternative tick control programs, and policy development and education. These areas were identified as top priorities to be developed to improve T&TBD control on the continent.
Background: Sumilarv 0.5G (Sumitomo Chemical Co., Ltd., Tokyo, Japan) is a granular insecticide developed for the control of mosquito and fly aquatic stages. The active ingredient is pyriproxyfen (4-phenoxyphenyl (RS)-2-(2-pyridyloxy) propyl ether), a juvenile hormone analogue that acts as an insect growth regulator. Sumilarv 0.5G functions by inhibition of adult emergence from pupae. In this study, the Tropical Pesticides Research Institute in Tanzania carried out laboratory, semifield, and full-field evaluation on a new candidate of pupicide, Sumilarv 0.5G. The present study, therefore, sought to test the bioefficacy of Sumilarv 0.5G in laboratory, semifield, and full-field conditions in Mabogini, northern Tanzania. Methods: Standard World Health Organization laboratory bioefficacy evaluations of Sumilarv 0.5G and untreated microcosms were prepared and monitored for inhibition of the larvae introduced to the habitats, while field plots were monitored for 5 weeks after the introduction of Sumilarv 0.5G using manufacturer-recommended doses. Results: Sumilarv 0.5G biolarvicide was highly efficacious in its pupicidal effect, with an adult emergence inhibition rate of up to 90% in all conditions. In both laboratory and semifield experiments, the emergence inhibition was dose-dependent, with the lowest adult emergence being recorded in association with the highest Sumilarv 0.5G dose of 0.03 ppm of active ingredient. Under field conditions, the application rate recommended by the manufacturer-5 mg ai per m 2-reduced the adult emergence rate by 90% to 96% for up to 5 weeks. Conclusion: We demonstrated the long-lasting biological activity of Sumilarv 0.5G under field conditions. Notably, the field efficacy was attained using the recommended dose of 5 mg per m 2 , thus making it economical to apply this product, which is capable of inhibiting mosquito productivity in natural habitats for longer periods than achieved by existing products, the efficacy of which is usually about 1 week.
Background: Sumilarv 0.5G (Sumitomo Chemical Co., Ltd., Tokyo, Japan) is a granular insecticide developed for the control of mosquito and fly aquatic stages. The active ingredient is pyriproxyfen (4-phenoxyphenyl (RS)-2-(2 – pyridyloxy) propyl ether), a juvenile hormone analogue that acts as an insect growth regulator. Sumilarv 0.5G functions by inhibition of adult emergence from pupae. In this study, the Tropical Pesticides Research Institute in Tanzania carried out laboratory, semifield, and full-field evaluation on a new candidate of pupicide, Sumilarv 0.5G. The present study, therefore, sought to test the bioefficacy of Sumilarv 0.5G in laboratory, semifield, and full-field conditions in Mabogini, northern Tanzania. Methods: Standard World Health Organization laboratory bioefficacy evaluations of Sumilarv 0.5G and untreated microcosms were prepared and monitored for inhibition of the larvae introduced to the habitats, while field plots were monitored for 5 weeks after the introduction of Sumilarv 0.5G using manufacturer-recommended doses. Results: Sumilarv 0.5G biolarvicide was highly efficacious in its pupicidal effect, with an adult emergence inhibition rate of up to 90% in all conditions. In both laboratory and semifield experiments, the emergence inhibition was dose-dependent, with the lowest adult emergence being recorded in association with the highest Sumilarv 0.5G dose of 0.03 ppm of active ingredient. Under field conditions, the application rate recommended by the manufacturer – 5 mg ai per m2 – reduced the adult emergence rate by 90% to 96% for up to 5 weeks. Conclusion: We demonstrated the long-lasting biological activity of Sumilarv 0.5G under field conditions. Notably, the field efficacy was attained using the recommended dose of 5 mg per m2, thus making it economical to apply this product, which is capable of inhibiting mosquito productivity in natural habitats for longer periods than achieved by existing products, the efficacy of which is usually about 1 week.
Background: Sumilarv 0.5G (Sumitomo Chemical Co., Ltd., Tokyo, Japan) is a granular insecticide developed for the control of mosquito and fly aquatic stages. The active ingredient is pyriproxyfen (4-phenoxyphenyl (RS)-2-(2 – pyridyloxy) propyl ether), a juvenile hormone analogue that acts as an insect growth regulator. Sumilarv 0.5G functions by inhibition of adult emergence from pupae. In this study, the Tropical Pesticides Research Institute in Tanzania carried out laboratory, semifield, and full-field evaluation on a new candidate of pupicide, Sumilarv 0.5G. The present study, therefore, sought to test the bioefficacy of Sumilarv 0.5G in laboratory, semifield, and full-field conditions in Mabogini, northern Tanzania. Methods: Standard World Health Organization laboratory bioefficacy evaluations of Sumilarv 0.5G and untreated microcosms were prepared and monitored for inhibition of the larvae introduced to the habitats, while field plots were monitored for 5 weeks after the introduction of Sumilarv 0.5G using manufacturer-recommended doses. Results: Sumilarv 0.5G biolarvicide was highly efficacious in its pupicidal effect, with an adult emergence inhibition rate of up to 90% in all conditions. In both laboratory and semifield experiments, the emergence inhibition was dose-dependent, with the lowest adult emergence being recorded in association with the highest Sumilarv 0.5G dose of 0.03 ppm of active ingredient. Under field conditions, the application rate recommended by the manufacturer – 5 mg ai per m2 – reduced the adult emergence rate by 90% to 96% for up to 5 weeks. Conclusion: We demonstrated the long-lasting biological activity of Sumilarv 0.5G under field conditions. Notably, the field efficacy was attained using the recommended dose of 5 mg per m2, thus making it economical to apply this product, which is capable of inhibiting mosquito productivity in natural habitats for longer periods than achieved by existing products, the efficacy of which is usually about 1 week.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.